Infinity Pharmaceuticals, Inc.
INFI
INFI was delisted on the 13th of September, 2023.
115 hedge funds and large institutions have $390M invested in Infinity Pharmaceuticals, Inc. in 2015 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 33 increasing their positions, 42 reducing their positions, and 30 closing their positions.
131% more call options, than puts
Call options by funds: $3.19M | Put options by funds: $1.38M
5.54% less ownership
Funds ownership: 106.17% → 100.63% (-5.5%)
11% less funds holding
Funds holding: 129 → 115 (-14)
12% less capital invested
Capital invested by funds: $442M → $390M (-$51.9M)
21% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 42
47% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$11M |
| 2 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$8.69M |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$8.18M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.33M |
| 5 |
DM
Deerfield Management
New York
|
+$3.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$21.2M |
| 2 |
State Street
Boston,
Massachusetts
|
-$14.1M |
| 3 |
Renaissance Technologies
New York
|
-$6.19M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$4.99M |
| 5 |
Charles Schwab
San Francisco,
California
|
-$3.88M |
INFI Hedge Fund Activity: Q4 2015 in Review
115 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Infinity Pharmaceuticals, Inc. (INFI) for Q4 2015, worth a combined $390M — down 12% from $442M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of INFI and 16 opened new positions — a net loss of 14 holders — while 42 trimmed existing stakes and 33 added.
The largest buyer was Millennium Management, adding an estimated $11M. The largest seller was Goldman Sachs, cutting an estimated $21.2M.
- 115 institutional investors held Infinity Pharmaceuticals, Inc. (INFI) as of Q4 2015, down from 129 in Q3 2015.
- Funds reported $390M of Infinity Pharmaceuticals, Inc. stock for Q4 2015, down 12% quarter-over-quarter.
- 16 funds opened new Infinity Pharmaceuticals, Inc. positions in Q4 2015 and 30 closed out, a net change of -14 holders.
- The largest Infinity Pharmaceuticals, Inc. buyer in Q4 2015 was Millennium Management, an estimated $11M added.
- The largest Infinity Pharmaceuticals, Inc. seller in Q4 2015 was Goldman Sachs, an estimated $21.2M sold.
Based on aggregated 13F filings for Q4 2015.